(R) LT System in Minimally Invasive Spine Surgery
CASTEL SAN PIETRO,
28 April 2021 - Medacta announced today the first surgery utilizing its M.U.S.T.
(R) LT, following clearance by the U.S. Food and Drug Administration (FDA). M.U.S.T. LT (Long Tab Screw System) is the new minimally invasive solution for posterior spine fixation in the percutaneous approach. Mainly focused on degenerative spine cases, M.U.S.T. LT expands the benefits of a percutaneous approach in spine deformity, tumors, and trauma applications. The first surgery employing M.U.S.T. LT has been recently performed in the U.S. by Stephen Tolhurst, M.D., at Texas Back Institute, in Plano, Texas.
EQS-News: Medacta Group SA: Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem
Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem
11.03.2021 / 19:00
(R) for S2-Alar-Iliac Fixation and Further Enhances its MySolutions
(R) Personalized Ecosystem
(R) for S2-alar-iliac fixation (S2AI) to its MySolutions
(R) personalized ecosystem.
MySpine is a patient-specific screw placement guide, which allows the surgeon to determine the preoperative 3D planning, based on CT images of the patient s spine. MySpine S2AI is Medacta s solution for a solid pelvis fixation achieved by means of screws which are inserted in the second sacral vertebra (S2) and protrude through the ala until the ilium walls.
EQS-News: Medacta Group SA: Medacta Adds the MyHip Planner and the MyHip Verifier Tools to its Personalized Medicine Solutions for Hip Replacement
(R) Verifier Tools to its Personalized Medicine Solutions for Hip Replacement
CASTEL SAN PIETRO,
15 February 2021 - Medacta is proud to announce that it has received clearance from the U.S. Food and Drug Administration (FDA) for its MyHip
(R) Planner and MyHip
(R) Verifier, after recently receiving CE marking and approval from Australia s Therapeutic Goods Administration (TGA) and from the Japanese Ministry of Health, Labour and Welfare (MHLW). These two promising innovative technologies will be introduced into all markets in which Medacta operates in the upcoming months.